Post-traumatic stress disorder

6 trials 1 recruiting MedDRA PT
6 Registered trials
1 Recruiting
5 Unique sponsors
2 Unique IMPs
4 Commercial trials
Drug classes (ATC)
— ATC code not specified 5
C Cardiology (ATC C) 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 1 substance
Beta-blocker 1 substance
Phase II: 3 Phase I/II: 1 Phase I: 2

Filter these 6 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 6 trials

Phase II

3 trials
  • Transcend Therapeutics Inc. Commercial
    METHYLONE
    2023-508381-16-00 1 country 2024 n=20
    Ended
  • Amsterdam UMC Academic
    IMP not specified
    2024-511042-39-00 1 country 2024 n=60
    Recruiting
  • Centre Hospitalier Regional Universitaire De Tours Academic
    PROPRANOLOL
    2023-504075-25-00 1 country n=34
    Pending

Phase I/II

1 trial
  • Transcend Therapeutics Inc. Commercial
    METHYLONE
    2023-505874-14-00 1 country 2024 n=16
    Ended

Phase I

2 trials
  • Protagenic Therapeutics Inc. Commercial
    IMP not specified
    2024-519316-13-00 1 country 2025 n=24
    Ended
  • Rest Therapeutics Commercial
    IMP not specified
    2023-505030-99-00 1 country n=36
    Not authorised
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Transcend Therapeutics Inc. Commercial 2 Phase II, Phase I/II 0
Protagenic Therapeutics Inc. Commercial 1 Phase I 0
Rest Therapeutics Commercial 1 Phase I 0
Amsterdam UMC Academic 1 Phase II 1
Centre Hospitalier Regional Universitaire De Tours Academic 1 Phase II 0
New trials by year
2024
3
2025
1
← All indication landscapes